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Background: Periodontitis is a bacteria-driven inflammatory bone loss disease. Previous studies showed that the
oral pathogen Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) stimulated the generation of
sphingosine 1 phosphate (S1P). In addition, S1P signaling regulated the migration of osteoclast precursors and
affected osteoclastogenesis. Furthermore, treatment with FTY720 (also called fingolimod, a modulator of multiple
S1P receptors) alleviated osteoporosis and suppressed arthritis in animals. This study determined the effect of
FTY720 on proinflammatory cytokine production and osteoclastogenesis in murine bone marrow cells with or
without A. actinomycetemcomitans stimulation.
Methods: Murine bone marrow-derived monocytes and macrophages (BMMs) were treated with vehicle ethanol
or FTY720, and were either unstimulated or stimulated for 0.5 to 6 h with A. actinomycetemcomitans. The protein
levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α in the media of BMMs were quantified by
enzyme-linked immunosorbent assay (ELISA). Protein expressions, including phosphorylated phosphoinositide 3-kinase
(p-PI3K), p-Akt, p-extracellular signal-regulated kinase (p-ERK), PI3K, Akt, and ERK were evaluated by Western blot. In
addition, murine bone marrow-derived pre-osteoclasts were treated with macrophage colony-stimulating factor (M-CSF)
and receptor activator of nuclear factor kappa-B ligand (RANKL) for three days. Then the cells were treated with either
vehicle or FTY720 and were either unstimulated or stimulated with A. actinomycetemcomitans for 4 to 24 h. Control
cells were treated with M-CSF alone with or without bacterial stimulation. Osteoclasts were stained by tartrate-resistant
acid phosphatase (TRAP) staining. The mRNA levels of osteoclastogenic factors, including nuclear factor of activated T-cells
cytoplasmic calcineurin-dependent 1 (Nfatc1), cathepsin K (Ctsk), acid phosphatase 5 (Acp5), osteoclast-associated receptor
(Oscar), and RANKL were quantified by quantitative real-time polymerase chain reaction (PCR).
Results: FTY720 dose-dependently inhibited IL-1β, IL-6, and TNF-α protein levels induced by A. actinomycetemcomitans
in BMMs compared with controls. Additionally, FTY720 attenuated p-PI3K, p-Akt, and p-ERK expressions induced by A.
actinomycetemcomitans. Furthermore, FTY720 suppressed osteoclastogenesis in bone marrow-derived pre-osteoclasts with
or without bacterial stimulation and reduced the mRNA levels of Nfatc1, Ctsk, Acp5, and Oscar, but not RANKL in bone
marrow-derived pre-osteoclasts.
Conclusion: FTY720 inhibited proinflammatory cytokine production and suppressed osteoclastogenesis, supporting
FTY720 as a potential therapy for inflammatory bone loss diseases.
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Periodontitis is a bacteria-driven inflammatory bone loss
disease. A. actinomycetemcomitans is an oral pathogen
associated with localized aggressive periodontitis. Oral
bacterial pathogens initiate a host inflammatory response,
leading to proinflammatory cytokine production, progres-
sive alveolar bone loss, and subsequent tooth loss [1]. One
of the hallmarks of periodontitis is inflammation-induced
osteoclastogenesis. While observed, the mechanisms associ-
ated with the inflammatory bone loss response induced by
oral pathogens have not been completely elucidated.
Previously, we showed that A. actinomycetemcomitans
stimulated the generation of sphingosine-1-phosphate
(S1P) in RAW 264.7 cells, a murine monocyte and
macrophage cell line [2]. S1P is a bioactive sphingolipid,
which can be generated in most mammalian cells
by various stimuli [3]. Intracellular S1P can be exported to
extracellular space by specific transporters. S1P binds to
five G protein-coupled S1P receptors (S1PR1-5) on the
plasma membrane initiating various cellular signaling
pathways [4, 5]. S1P signaling plays an important role
in regulating cell growth, proliferation, adhesion,
chemotaxis, cytokine production, and bone homeosta-
sis [4, 6–8].
S1P signaling affects the pathogenesis of many diseases,
including inflammatory diseases, arthritis, and osteoporosis
[9–11]. The synovial fluid of rheumatoid arthritis patients
exhibits significantly higher levels of S1P than their non-
inflammatory osteoarthritis counterparts [12]. Additionally,
S1P signaling controls the migration of monocytes and
macrophages (osteoclast precursors) from blood circulation
to bone tissues [7, 8] and stimulates the generation of
RANKL, an osteoclastogenic factor, which affects bone
homeostasis [13]. Furthermore, high circulating S1P levels
observed in postmenopausal women are positively corre-
lated with their bone resorption markers [14]. However,
the roles of S1P signaling in modulating proinflammatory
cytokine release and osteoclastogenesis induced by oral
pathogens has not been defined.
FTY720 {2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-pro-
panediol hydrochloride} was synthesized by structural
modification of myriocin, a fungal metabolite from Isa-
claria sinclarii, a traditional herb used in Eastern medi-
cine [15]. FTY720 is phosphorylated to p-FTY720 by
sphingosine kinase. P-FTY720 functions as a noncom-
petitive inhibitor of multiple S1PRs [16, 17]. P-FTY720
blocks S1P signaling by inducing the internalization and
partial degradation of S1PRs [16]. FTY720 has been
shown as a potent immune suppressant with low tox-
icity. It has been used in clinical trials to treat relapsing
multiple sclerosis and prevent the rejection of renal
transplant [18, 19]. Additionally, treatment with FTY720
alleviated ovariectomy-induced osteoporosis in mice [7]
and attenuated arthritis in mice induced by arthrogenicanti-collagen II antibodies cocktail and lipopolysacchar-
ide, as compared with control treatment [20].
Monocytes and macrophages are major sources of
proinflammatory cytokines in chronic inflammatory
diseases. During inflammatory pathogenesis, bacterial
pathogens activate various cellular signaling cascades
including phosphoinositide 3-kinase (PI3K)-Akt (also
known as protein kinase B), mitogen-activated protein
kinases (MAPKs), and nuclear factor kappa-B (NF-κB)
pathways. The MAPKs include the extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and
p38 MAPK. Activation of these signaling pathways results
in proinflammatory cytokine release. Additionally, mono-
cytes and macrophages are osteoclast precursors, which
can fuse to form multinucleated mature osteoclasts leading
to bone loss [21]. Osteoclastogenesis is regulated by cyto-
kines, including M-CSF and RANKL, which are essential
for osteoclastogenesis [22]. M-CSF is essential for the sur-
vival and proliferation of osteoclast progenitors and macro-
phages, while RANKL is important for the differentiation
of osteoclasts [22]. Additionally, nuclear factor of activated
T-cells cytoplasmic calcineurin-dependent 1 (Nfatc1) is
considered the master transcription factor during osteoclast
differentiation [23]. Nfatc1 regulates transcription of many
osteoclastogenic genes, including cathepsin K (Ctsk), acid
phosphatase 5 (Acp5), and osteoclast-associated receptor
(Oscar) [24, 25]. Although previous studies demonstrated
that FTY720 inhibited immune response and attenuated
bone loss [7, 18–20], the mechanisms associated with the
roles of FTY720 on modulating inflammatory diseases
and bone loss diseases have not yet been completely
clarified. In this study, we elucidated the mechanisms
associated with the effects of FTY720 in proinflamma-
tory cytokine production and osteoclastogenesis with
or without A. actinomycetemcomitans stimulation.
Results
FTY720 dose-dependently inhibited IL-1β, IL-6, and TNF-α
protein levels induced by A. actinomycetemcomitans in
BMMs
Because FTY720 inhibited inflammatory response in
previous in vivo studies [26], we hypothesized that
FTY720 regulated the proinflammatory responses
induced by A. actinomycetemcomitans. To test our
hypothesis, BMMs derived from C57BL/6 mice were
treated with either vehicle (ethanol) or FTY720 (2 to
8 μM) for 30 min. Then the cells were either unstimu-
lated or stimulated with A. actinomycetemcomitans
(1.5 CFU/cell) for 6 h. The protein levels of IL-1β, IL-
6, and TNF-α in cell culture media were quantified.
As shown in Fig. 1a-c, FTY720 significantly sup-
pressed IL-1β, IL-6, and TNF-α expressions induced
by A. actinomycetemcomitans in a dose-dependent
manner compared with the control treatment. FTY720
Fig. 1 FTY720 dose-dependently inhibited IL-1β, IL-6, and TNF-α expressions induced by A. actinomycetemcomitans in BMMs. Murine BMMs
were treated with vehicle (ethanol) or FTY720 (2 to 8 μM) for 30 min. Then the cells were either unstimulated or stimulated for 6 h with A.
actinomycetemcomitans (Aa) (1.5 CFU/cell). a IL-1β, (b) IL-6, and (c) TNF-α protein levels in the cell culture media of BMMs were analyzed
by ELISA. d Cell viability was tested in BMMs treated with vehicle or FTY720 (2 to 8 μM) for 8 h. Data are expressed as mean ± SEM (n = 3,
*p < 0.05, **p < 0.01, ***p < 0.001)
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TNF-α by 69.1 % induced by A. actinomycetemcomi-
tans compared with the control treatment. FTY720
(4 μM) also reduced IL-1β by 58.3 %, IL-6 by 59.5 %,
and TNF-α by 53.5 % induced by A. actinomycetemco-
mitans compared with the control treatment. FTY720
(2 to 8 μM) did not induce cell death in BMMs 8 h after
treatment (Fig. 1d). These data supported that FTY720 sup-
pressed the proinflammatory cytokine response induced by
the oral pathogen A. actinomycetemcomitans.
FTY720 attenuated p-PI3K, p-Akt, and p-ERK expressions
induced by A. actinomycetemcomitans in BMMs
To further elucidate which signaling pathways were af-
fected by FTY720 in regulating the immune response
induced by A. actinomycetemcomitans, we performed
Western blot assays in BMMs treated with vehicle (etha-
nol) or FTY720 (8 μM), with or without A. actinomyce-
temcomitans stimulation. As shown in Fig. 2a-d, FTY720
treatment decreased p-PI3K by 92.5 %, p-Akt by 65.9 %,
and p-ERK by 54.0 % 30 min after bacterial stimulation
compared with the control treatment. FTY720 reduced
p-PI3K by 75.2 %, p-Akt by 76.9 %, and p-ERK by
59.1 % 60 min after bacterial stimulation compared with
the control treatment. Additionally, FTY720 attenuated
p-PI3K by 43.6 %, p-Akt by 59.2 %, and p-ERK by
50.0 % in cells without bacterial stimulation compared
with the control treatment. The protein levels of p-NF-κB p65, p-JNK, p-p38 MAPK, and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were similar between
FTY720-treated cells and vehicle-treated cells before or
after bacterial stimulation (data not shown). These results
supported that FTY720 specifically attenuated the PI3K,
Akt, and ERK signaling pathways, which could contribute
to the down-regulation of the proinflammatory cytokine re-
sponse stimulated by A. actinomycetemcomitans.
FTY720 suppressed osteoclastogenesis in bone
marrow-derived pre-osteoclasts with or without
bacterial stimulation
Osteoclasts originate from the fusion of monocytes and
macrophages [27]. It has been recognized that phosphoi-
nositides signaling controls the activation of Nfatc1 and
influences osteoclastogenesis [28]. Furthermore, proin-
flammatory cytokines promote the differentiation of
osteoclasts [1]. Since FTY720 significantly inhibited PI3K
signaling and attenuated proinflammatory cytokine expres-
sion induced by A. actinomycetemcomitans, we hypothe-
sized that FTY720 could further inhibit osteoclastogenesis.
To test our hypothesis, murine bone marrow cells were
treated with M-CSF (50 μg/mL) for two days to allow
bone marrow progenitor cells to differentiate into bone
marrow-derived pre-osteoclasts. To determine if FTY720
could inhibit osteoclastogenesis induced by RANKL, bone
marrow-derived pre-osteoclasts were treated with M-CSF
(50 μg/mL) and RANKL (100 ng/mL) for three days; then
Fig. 2 FTY720 attenuated p-PI3K, p-Akt, and p-ERK expressions induced by A. actinomycetemcomitans in BMMs. Murine BMMs were treated with vehicle
(ethanol) or FTY720 (8 μM) for 30 min. Then the cells were either unstimulated or stimulated with A. actinomycetemcomitans (Aa) (1.5 CFU/cell) for 30 to
120 min. a P-PI3K, PI3K, p-Akt, Akt, p-ERK, and ERK expressions were evaluated by Western blot. b P-PI3K protein density, (c) P-Akt protein density, and (d)
P-ERK protein density were analyzed by Quantity One Software and normalized by total protein expression, respectively. Data are expressed as mean ±
SEM (n= 3, *p< 0.05, *** p< 0.001)
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CSF (50 μg/mL) and RANKL (100 ng/mL). Cells were
treated with FTY720 (2 μM) or vehicle (ethanol) for 24 h
(Fig. 3a). Additionally, to determine if FTY720 could at-
tenuate osteoclastogenesis induced by A. actinomycetem-
comitans, bone marrow-derived pre-osteoclasts were
treated with M-CSF (50 μg/mL) and RANKL (100 ng/mL)
for three days. To reduce the background of osteoclasto-
genesis induced by RANKL, the media were changed with
media containing only M-CSF (50 μg/mL) without
RANKL. The cells were treated for 30 min with vehicle or
FTY720 (2 μM). Then the cells were either unstimulated
or stimulated for 24 h with A. actinomycetemcomitans
(0.5 CFU/cell), in the presence of FTY720 or vehicle
(Fig. 3a). Control cells were treated with media con-
taining only M-CSF (50 μg/mL) with or without bac-
terial stimulation. Osteoclasts were detected by
tartrate-resistant acid phosphatase (TRAP) staining
24 h after FTY720 or vehicle treatment. As shown in
Fig. 3b, there were no TRAP+ osteoclasts in cells
treated with only M-CSF with or without bacterial
stimulation. There were many TRAP+ multinucleated
osteoclasts in cells treated with vehicle in the presence
of both M-CSF and RANKL with or without bacterial
stimulation. In contrast, FTY720 (2 μM) treatmentdecreased both size and number of TRAP+ multinucleated
osteoclasts compared with vehicle groups. Quantification of
the number of osteoclasts showed that there was a 1.9-fold
increase of the number of osteoclasts in cells treated
with M-CSF and RANKL stimulated with A. actinomy-
cetemcomitans compared with cells treated with M-CSF
and RANKL without bacterial stimulation (Fig. 3c).
FTY720 treatment reduced the number of osteoclasts
by 53.2 % in cells treated with M-CSF and RANKL
without bacterial stimulation, and decreased the num-
ber of osteoclasts by 64.3 % in cells treated with M-CSF
and RANKL with bacterial stimulation, as compared
with vehicle controls, respectively (Fig. 3c). Quantifica-
tion of total area of osteoclasts per image revealed that
FTY720 reduced the area of osteoclasts by 74.2 % in
cells treated with M-CSF and RANKL without bacterial
stimulation, and FTY720 decreased the area of osteo-
clasts by 71.4 % in cells treated with M-CSF and
RANKL with bacterial stimulation (Fig. 3d). FTY720
(2 μM) treatment for 24 h did not induce cell death in
bone marrow-derived pre-osteoclast (Fig. 3e). These
data demonstrated that FTY720 suppressed osteoclas-
togenesis in bone marrow-derived pre-osteoclasts
treated with M-CSF and RANKL with or without bac-
terial stimulation.
Fig. 3 FTY720 suppressed osteoclastogenesis in bone marrow-derived pre-osteoclasts treated with or without A. actinomycetemcomitans (Aa)
stimulation. a Bone marrow (BM) cells were treated as described in Methods. b Representative images show TRAP-stained cells with or without A.
actinomycetemcomitans stimulation. Pictures were taken at 100× magnification. c Number of TRAP+ multinucleated (more than 3 nuclei) osteoclasts/well
(96-well) were quantified. d Total areas for osteoclasts/image were quantified. e Cell viability was tested in bone marrow-derived pre-osteoclasts treated
with vehicle or FTY720 (2 μM) for 24 h. Data are expressed as mean ± SEM (n= 4, ***p< 0.001)
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Nfatc1, Ctsk, Acp5, and Oscar in bone marrow-derived
pre-osteoclasts with or without bacterial stimulation
To elucidate the mechanisms associated with the role of
FTY720 in osteoclastogenesis, we analyzed the mRNA
expressions of various kinds of osteoclastogenic factors,including Nfatc1, Ctsk, Acp5, Oscar, and RANKL in
bone marrow-derived pre-osteoclasts treated for 4 or for
24 h with FTY720 (2 μM) or vehicle (ethanol), with or
without A. actinomycetemcomitans stimulation. As shown
in Fig. 4a-d, cells treated with both M-CSF and RANKL sig-
nificantly increased the mRNA levels of Nfatc1, Ctsk, Acp5,
Fig. 4 (See legend on next page.)
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Fig. 4 FTY720 significantly decreased Nfatc1, Ctsk, Acp5, and Oscar expressions in bone marrow-derived pre-osteoclasts with or without A.
actinomycetemcomitans (Aa) stimulation. Bone marrow-derived pre-osteoclasts were treated as described in Methods. Cells were treated
with vehicle (ethanol) or FTY720 (2 μM) for 30 min. Then the cells were either unstimulated or stimulated with A. actinomycetemcomitans
(Aa) (0.5 CFU/cell) in the presence of vehicle or FTY720 for 4 h (a-d) or for 24 h (e-h). a, e Nfatc1 mRNA, (b, f) Ctsk mRNA, (c, g) Acp5 mRNA,
and (d, h) Oscar mRNA levels were normalized by an endogenous control GAPDH expression and expressed as fold change compared with control group.
Data are expressed as mean ± SEM (n= 3, *p< 0.05, **p< 0.01, ***p< 0.001)
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M-CSF alone. In cells treated with FTY720 for 4 h without
bacterial stimulation (Fig. 4a), there was a 22.0 % significant
reduction of Nfatc1 mRNA expression as compared with
vehicle control. However, there were no significant differ-
ences of the mRNA levels of Ctsk, Acp5, and Oscar be-
tween FTY720-treated cells and vehicle-treated cells
(Fig. 4b-d). In cells treated with FTY720 for 24 h without
bacterial stimulation (Fig. 4. e-h), FTY720 significantly
decreased the mRNA levels of Ctsk by 36.1 %, Acp5 by
51.5 %, and Oscar by 47.3 % compared with those
levels in vehicle-treated cells. However, there was no
significant difference in Nfatc1 mRNA expression be-
tween these two groups.
In cells treated with vehicle and stimulated with A.
actinomycetemcomitans for 4 h (Fig. 4a-d), there was a
1.8-fold increase of Nfatc1 and a 3.6-fold increase of
Oscar mRNA expression compared with those in cells
without bacterial stimulation. FTY720 significantly re-
duced the mRNA levels of Nfatc1 by 36.5 %, Ctsk by
28.9 %, Acp5 by 23.6 %, and Oscar by 27.0 % compared
with vehicle controls. In cells treated with vehicle stimu-
lated with bacteria for 24 h (Fig. 4e-h), we observed a
1.3-fold increase of Ctsk and a 1.6-fold increase of Acp5
mRNA levels compared with those levels in cells treated
with M-CSF and RANKL without bacterial stimulation.
FTY720 significantly decreased the mRNA levels of Ctsk
by 45.4 %, Acp5 by 47.7 %, and Oscar by 48.5 % com-
pared with vehicle controls. However, there was no sig-
nificant difference in Nfatc1 mRNA expression at 24 h
between FTY720 treated-cells and vehicle-treated cells.
These data supported that FTY720 decreased the mRNA
expressions of osteoclastogenic factors, including Nfatc1,
Ctsk, Acp5, and Oscar in bone marrow-derived pre-
osteoclasts treated with M-CSF and RANKL with or
without bacterial stimulation, which subsequently influ-
enced the osteoclastogenesis.
Discussion
Previous studies showed that FTY720, a modulator of
multiple S1P receptors, exerted immunosuppressive ac-
tivity and attenuated bone loss in mice [7, 18–20]. How-
ever, the mechanisms associated with the roles of
FTY720 on modulating inflammatory diseases and bone
loss diseases have not yet been completely elucidated. In
this in vitro study, we demonstrated that FTY720suppressed PI3K-Akt and ERK signaling pathways and
attenuated IL-1β, IL-6, and TNF-α expressions in-
duced by A. actinomycetemcomitans. Importantly, we
first demonstrated that FTY720 suppressed osteoclas-
togenesis in bone marrow-derived pre-osteoclasts.
Mechanistically, we demonstrated that FTY720 inhib-
ited the expressions of osteoclastogenic factors, in-
cluding Nfatc1, Ctsk, Acp5, and Oscar. Our study
suggested that S1PR signaling pathways might be in-
volved in the modulation of proinflammatory response
induced by bacterial stimulation and may affect the
osteoclastogenesis.
Previously, FTY720 was shown to exhibit an immuno-
suppressive effect in vivo [18, 19]. Early studies demon-
strated that this effect was mainly caused by internalization
and down-regulation of S1PR1 by FTY720 [26, 29], which
resulted in the suppression of the egress of mature lympho-
cytes from the secondary lymphoid organs to peripheral
blood and lymph [30]. In the current in vitro study, we
demonstrated that FTY720 had a direct anti-inflammatory
effect by suppressing IL-1β, IL-6 and TNF-α expression in-
duced by the oral pathogen A. actinomycetemcomitans.
This might be caused by the down-regulation of PI3K, Akt,
and ERK signaling pathways by FTY720 in BMMs. Previous
studies showed that human peripheral blood mononuclear
cells (PBMCs) treated with a PI3K inhibitor, wortmannin,
significantly inhibited LPS-induced chemokine C-X-C motif
ligand 8 (CXCL8) and IL-6 release [31]. Additionally,
PBMCs treated with pertussis toxin, a small G protein
inhibitor, inhibited LPS-induced Akt phosphorylation and
reduced the generation of CXCL8 and IL-6 [31]. Further-
more, murine macrophages treated with trametinib, a
highly potent ERK inhibitor, significantly reduced LPS-
induced TNF-α mRNA and protein secretion [32]. Since
PI3K, Akt, and ERK signaling pathways were up-regulated
by bacterial stimulation, and activation of these signaling
pathways contributed to the production of proinflamma-
tory cytokines, suppression of these signaling pathways by
FTY720 might subsequently reduce IL-1β, IL-6 and TNF-α
expressions induced by bacterial stimulation. Previously,
Noda et al. [33] also demonstrated that FTY720 inhibited
the production of LPS-induced proinflammatory cyto-
kine IL-1β, IL-6, and TNF-α in microglia. In accord-
ance with Noda et al., our study demonstrated that
FTY720 suppressed IL-1β, IL-6 and TNF-α expres-
sions induced by A. actinomycetemcomitans.
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multiple S1PRs, researchers continue to debate as to
which S1PRs are regulated by p-FTY720. Early studies
supported that p-FTY720 bound with higher affinity
with S1PR1, 3, 4 and 5, and served as a S1P agonist [34,
35]. However, later studies demonstrated that p-FTY720
functioned as a noncompetitive inhibitor of multiple
S1PRs [16, 17]. Graler et al. [16] demonstrated that
FTY720 blocked S1P signaling through S1PR1, 2, and 5
by inducing their internalization and intracellular partial
degradation without affecting S1PR3 or S1PR4. Another
study showed that human monocyte-derived dendritic
cells treated with both FTY720 and p-FTY720 resulted
in decreased S1PR1 and S1PR4 levels [17]. Future stud-
ies need to determine which of the five S1PRs might play
a role in regulating the inflammatory response stimu-
lated by A. actinomycetemcomitans.
In addition to modulating inflammatory response,
previous studies demonstrated that S1P signaling was
critical in modulating bone homeostasis [7, 14]. Lee
et al. [14] showed that S1P levels were significantly
higher in postmenopausal women than those in the pre-
menopausal women and men, and the higher S1P levels
in postmenopausal women were positively correlated
with their bone resorption marker. In contrast, blocking
S1P signaling by FTY720 inhibited osteoporosis in mice
with ovariectomy [7]. Ishii et al. [7] explained that the
anti-osteoporotic role of FTY720 is mainly caused by the
inhibition of the migration of osteoclast precursors from
the circulation to bone tissues. In the current in vitro
assay, we demonstrated that FTY720 suppressed the
differentiation of osteoclasts and attenuated the expres-
sions of osteoclastogenic factors, including Nfatc1, Ctsk,
Acp5, and Oscar.
Osteoclastogenesis involves fusion of osteoclast pre-
cursors to form multinucleated mature osteoclasts. It
has been recognized that membrane lipids, especially
phosphoinositides, are key signaling molecules that
regulate osteoclastogenesis [28]. Activation of PI3K trig-
gers the Ca2+ release followed by activation of Nfatc1, a
master transcription factor for osteoclastogenic gene
regulation [23, 28]. In this study, we demonstrated that
FTY720 attenuated p-PI3K levels in BMMs before or
after bacterial stimulation compared with vehicle treat-
ment. Previously, Graler et al. [16] showed that HTC4
cells (rat hepatoma cells) treated with FTY720 decreased
calcium release. We observed significantly decreased
mRNA levels of Nfatc1, Ctsk, Acp5, and Oscar in
FTY720-treated cells with or without bacterial stimu-
lation compared with those in the vehicle-treated cells.
The down-regulation of these osteoclastogenic factors
by FTY720 might be associated with the decreased
p-PI3K and possibly reduced intracellular calcium
levels in FTY720-treated cells before or after bacterialstimulation. Since RANKL induces osteoclastogenesis
via activation of Nfatc1 [36], down-regulation of
Nfatc1 by FTY720 could inhibit osteoclastogenesis in-
duced by RANKL without bacterial stimulation. In
addition, reducing IL-1β, IL-6 and TNF-α expressions
induced by bacterial stimulation by FTY720 could fur-
ther attenuate osteoclastogenesis. In this study, we ob-
served significant reductions of Nfatc1 mRNA levels
by FTY720 at 4 h after treatment compared with ve-
hicle controls, while we did not observe this signifi-
cant reduction of Nfatc1 mRNA levels at 24 h in
FTY720-treated cells compared with vehicle controls
with or without bacterial stimulation. This suggests
that activation of Nfatc1 is an early event that might
occur before the activation of Ctsk, Acp5 and Oscar.
A previous study showed that low doses of FTY720
(20 to 100 nM) did not inhibit osteoclastogenesis in
BMMs treated with RANKL and M-CSF for 4 days [13].
In this study, FTY720 (2 μM) suppressed osteoclasto-
genesis in bone marrow-derived pre-osteoclasts treated
with M-CSF and RANKL with or without bacterial
stimulation. Our study suggested that it might require
higher doses of FTY720 (≥2 μM) to suppress p-PI3K
and Nfatc1 expressions. Ryu et al. [13] demonstrated
that S1P enhanced the expression of RANKL in osteo-
blasts, and FTY720 (10 nM) was potent to suppress
S1P-induced RANKL expression in osteoblasts. In
addition, they showed that FTY720 (10 nM) inhibited
osteoclastogenesis induced by S1P in a co-culture of
BMMs and osteoblasts [13]. Because RANKL is mainly
produced in osteoblasts and mesenchymal stem cells, we
did not observe a significant difference in RANKL expres-
sion between FTY720-treated cells and vehicle-treated
cells in this single culture of bone marrow-derived pre-
osteoclasts. As FTY720 is a modulator of multiple S1PRs,
future studies need to determine which of the five S1PRs
play a major role in regulating PI3K pathway, calcium re-
lease, and the expressions of various osteoclastogenic fac-
tors, including RANKL, Nfatc1, Ctsk, Acp5, and Oscar.
Conclusions
FTY720 inhibited proinflammatory cytokine production
in BMMs and suppressed osteoclastogenesis in bone
marrow-derived pre-osteoclasts with or without A. acti-
nomycetemcomitans stimulation, supporting FTY720 as
a potential therapy for inflammatory bone loss diseases.
Methods
Murine bone marrow-derived monocytes and macrophages
(BMMs) and reagents
Six to eight-week-old male C57BL/6 mice were pur-
chased from Jackson Laboratory (Bar Harbor, ME, USA).
Bone marrow cells were harvested from the femurs and
tibias of mice. Murine bone marrow cells were cultured
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media (Life Technologies, Grand Island, NY, USA) con-
taining 10 % fetal bovine serum (FBS), 100 U/mL peni-
cillin, and 100 μg/mL streptomycin to remove adherent
cells. To allow bone marrow progenitor cells to differen-
tiate into BMMs, non-adherent cells were transferred to
new tissue culture dishes and cultured for 7 days in
complete MEM-α media supplemented with 50 ng/mL
murine recombinant M-CSF (R&D systems, Minneap-
olis, MN, USA). After seven days, the suspended cells
were discarded and the attached BMMs were plated in
tissue culture dishes. FTY720 was obtained from Santa
Cruz biotechnology (Dallas, TX, USA), diluted in ethanol
(10 mM), and stored at - 20 °C.Culture of A. actinomycetemcomitans
A. actinomycetemcomitans (ATCC 43718, serotype b, strain
Y4) was purchased from American Type Culture Collection
(Manassas, VA, USA). Bacterial colonies were grown on
Difco™ brain heart infusion agar plates (BD Biosciences,
Sparks, MD, USA) and cultured in Bacto™ brain heart infu-
sion broth (BD Biosciences) at 37 °C with 10 % CO2 for
24 h. Bacteria were centrifuged, washed with PBS with 5 %
glycerol, and resuspended in PBS with 5 % glycerol. Bacter-
ial concentration was determined by measuring bacterial
optical density and followed by plating on brain heart infu-
sion agar plates (OD600 = 1, about 3 × 10
7 colony forming
unit, CFU/mL).Enzyme-linked immunosorbent assay (ELISA)
IL-1β, IL-6, and TNF-α cytokine levels in the cell culture
media of BMMs were quantified by ELISA kits (R& D
Systems). The protein concentrations from cell lysates
were determined by a DC protein Assay Kit (Bio-Rad
Laboratories, Hercules, CA, USA). The concentration of
cytokines was normalized by protein concentration in
cell lysates.Cell viability assay
Bone marrow cells (1 × 105/well) in a 96-well plate were
incubated with either vehicle (ethanol) or FTY720 (2 to
8 μM) for 8 to 24 h. The cell viability was analyzed by
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA).Western blot assay
BMMs were lysed in RIPA protein lysis buffer (Cell Sig-
naling Technology, Danvers, MA, USA). Western blot
was performed as previously described [37]. The anti-
bodies to p-PI3K, PI3K, p-Akt, Akt, p-ERK, ERK, p-JNK,
p-p38, p-NF-κBp65, and GAPDH were purchased from
Cell Signaling Technology (Danvers, MA, USA).Osteoclastogenesis assay and tartrate-resistant acid
phosphatase (TRAP) staining
Murine bone marrow cells were cultured for 18 h in tis-
sue culture dishes in complete MEM-α media to remove
adherent cells. Non-adherent cells were transferred to
new tissue culture dishes and cultured for 2 days in
complete MEM-α media, supplemented with 50 ng/mL
murine recombinant M-CSF to allow cells to differenti-
ate into pre-osteoclasts. At day 3, cells were plated at a
density of 1×106 cells/well in 12-well plates or 1.5 × 105
cells/well in 96-well plate, and cultured in complete
MEM-α media, supplemented with either 50 ng/mL
murine recombinant M-CSF alone (control) or with both
50 ng/mL M-CSF and 100 ng/mL RANKL (R&D Systems).
At day 6, the media were changed and the cells were cul-
tured in fresh MEM-α media containing 50 ng/mL M-CSF
with or without 100 ng/mL RANKL. The cells were treated
with either FTY720 (2 μM) or vehicle (ethanol) for 30 min.
Then the cells were either unstimulated or stimulated with
A. actinomycetemcomitans (0.5 CFU/cell) in the presence
of FTY720 or vehicle for 4 h or for 24 h. Control cells were
treated with M-CSF alone with or without bacterial stimu-
lation. TRAP staining was performed in the cells using a
leukocyte acid phosphatase kit (Sigma Aldrich, St. Louis,
MO, USA) 24 h after FTY720 treatment. Pictures were
taken by a Nikon Eclipse TS-100 inverted microscope.
Image analysis was performed using Visiopharm 5.0 soft-
ware (Visiopharm, Hoersholm, Denmark).RNA extraction and real time polymerase chain reaction
(PCR)
The RNA extraction, reverse transcription, and real
time PCR were performed as previously described [2].
The following amplicon primers were obtained from
Life Technologies: Nfatc1 (Mm00479445_m1), Ctsk
(Mm00484039_m1), Acp5 (Mm00475698_m1), Oscar
(Mm00558665_m1), RANKL (Mm00441906_m1), and
GAPDH (Mm99999915_g1). Amplicon concentration
was determined using threshold cycle values compared
with standard curves for each primer. Sample mRNA levels
were normalized to an endogenous control GAPDH ex-
pression and expressed as fold changes compared with con-
trol groups.Statistical analyses
All experiments were performed in triplicate with bone
marrow cells from mice. Data were analyzed by one-way
ANOVA with Holm-Sidak’s multiple comparisons test.
All statistical tests were performed using GraphPad
Prism software (GraphPad Software Inc., La Jolla CA,
USA). Values are expressed as mean ± standard error of
the mean (SEM). A P value of 0.05 or less was consid-
ered significant.
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